IBAH, Inc. Announces Financial Results for Q2 1995

Strategic Insights -

IBAH, a leading provider of product development services to the pharmaceutical, biotechnology, and medical device industries, announced its financial results for the second quarter ended June 30, 1995. The Company reported a 42% increase in pro forma net revenues to $11.4 million, driven by significant growth in the European Clinical Services Division. However, the Company also experienced a lower-than-expected performance in achieving new sales, which impacted its net loss. Despite this, IBAH is optimistic about its future prospects, having finalized the divestiture of its Drug Delivery Services Division and secured a private equity placement of $7.0 million.

Key Takeaways:

  • IBAH reported pro forma net revenues of $11.4 million, a 42% increase from $8.0 million in the second quarter of 1994.
  • The European Clinical Services Division drove the growth in net revenues, while the U.S. Clinical Services Division reported a 7% increase compared to the same period in 1994.
  • IBAH's pro forma net loss was $1.7 million, or $0.12 per share, compared to a net loss of $0.9 million, or $0.07 per share, in the second quarter of 1994.
  • The Company finalized the divestiture of its Drug Delivery Services Division, allowing IBAH to focus on its core CRO and Pharmaceutics businesses.
  • IBAH secured a private equity placement of $7.0 million through the issuance of convertible preferred stock and warrants.

Statistics:

  • Pro forma net revenues: $11.4 million (up 42% from $8.0 million in Q2 1994)
  • Pro forma net loss: $1.7 million, or $0.12 per share, compared to a net loss of $0.9 million, or $0.07 per share, in Q2 1994
  • Private equity placement: $7.0 million
  • Project backlog (as of June 30, 1995): $82 million (unchanged from the end of Q1 1995)

Sources:

  • IBAH, Inc. press release (Aug. 14, 1995)
  • Nasdaq: IBAH
  • /PRNewswire/